<i>ASXL1</i> truncating mutations drive leukemic resistance to T cell attack

Abstract excerpt

<h4>Summary</h4> We previously found that specific exhausted T cell subsets defined response, but not resistance, to donor lymphocyte infusions (DLI), a curative immunotherapy for leukemic relapse following allogeneic stem cell transplant (SCT). To identify leukemia molecular pathways that drive resistance, we analyzed whole exome and targeted mutation panel sequencing in two independent cohorts of DLI-treated pa...

Topics

Open a Topic to create a Post that cites this publication.

• Acute Myeloid Leukemia Research
• CAR-T cell therapy research
• Cell Line, Tumor
• Chronic Myeloid Leukemia Treatments
• CRISPR and Genetic Engineering
• Drug Resistance, Neoplasm
• Myeloproliferative Neoplasms: Diagnosis and Treatment
• T-cell and B-cell Immunology

Identifiers and source

Literature Corpus work

c70a63ba-b368-544b-817f-d16f9db6ed51

DOI

10.1101/2025.05.29.656798